[ad_1]
Spyridoula Vasileiou, PhD, discusses the potential role of ALVR109, a SARS-CoV-2 virus-specific T-cell therapy, for the treatment of coronavirus disease 2019.
Spyridoula Vasileiou, PhD, Postdoctoral Associate, Baylor College of Medicine, discusses the potential role of ALVR109, a SARS-CoV-2 virus-specific T-cell therapy, for the treatment of coronavirus disease 2019 (COVID-19).
A preclinical analysis evaluated the endogenous T cell responses of COVID-19 patients who recovered from the virus without hospitalization, as well as immune activity against possible SARS-CoV-2 target antigens. The aim of the study was to identify SARS-CoV-2 target antigens that had immunodominant recognition by immunocompetent individuals, Vasileiou explains.
The results of the analysis, which were presented virtually during the 2020 ASH Annual Meeting and Expo, showed a mean 9.3 ± 1-fold expansion of cells that were composed almost exclusively of CD3 + T cells, with a mixture of cytotoxic T cells. and auxiliaries. These cells had a phenotype compatible with effector function and memory potential, as evidenced by the positive regulation of the activation markers CD25, CD69 and CD28 and the expression of the central memory and effector markers, with minimal expression of PD. -1 or TIM-3.
Furthermore, immune activity was confirmed with the IFNg ELIspot assay. This demonstrated that the immune response was mediated by subsets of CD4 and CD8 T cells. In addition, most of the interferon gamma-producing cells produced TNF-alpha characteristics, which were associated with superior clinical outcomes. Live. These findings suggest that ALVR109 could be a potentially safe and effective treatment for COVID-19 patients, Vasileiou concludes.
